Bailey Evan Prescott 4

What Happened
Evan Prescott, Chief Medical Officer of Applied Therapeutics (APLT), received a compensatory grant of 437,500 restricted stock units (RSUs) on 2025-12-19 and, as part of the company’s merger, had 1,321,230 total securities converted/cancelled and exchanged for the merger consideration. At the merger Effective Time (Jan 28, 2026) each outstanding share and RSU was cancelled and converted into $0.088 cash per share (net to the seller) plus one non-tradeable contingent value right (CVR) per share. The cash portion of the conversion for the reported 1,321,230 securities is about $116,268.24. The Form 4 reporting these transactions was filed on 2026-02-03.

Key Details

• Transactions reported: Grant of 437,500 RSUs on 2025-12-19 (grant price $0.00). Dispositions reported 2026-02-03 reflecting the merger conversion: 1,235,915 shares (to issuer), 60,901 shares (change-of-control), and two derivative disposals of 19,531 and 4,883 shares.
• Effective Time of Merger: January 28, 2026; merger consideration = $0.088 per share (cash) + one CVR per share.
• Approximate cash received for reported securities: $116,268.24 (1,321,230 × $0.088), plus CVRs (non-tradeable, contingent future payments).
• RSUs: Per the merger terms, all RSUs (vested or unvested) were deemed vested and converted into the merger consideration.
• Options: Merger terms state out‑of‑the‑money options (exercise price ≥ $0.088) were vested immediately before the Effective Time and then cancelled if unexercised.
• Filing: Form 4 filed 2026-02-03. The dispositions took effect at the Jan 28, 2026 Effective Time; see filing for exact post-transaction holdings and the note that total holdings were adjusted to correct a prior administrative understatement.

Context
This is a merger-related conversion/cash-out rather than a voluntary open‑market sale by the insider. The cash received is fixed at $0.088 per converted share; the CVRs may provide additional contingent value in the future subject to their terms. Such merger conversions reflect structural corporate action rather than a straightforward buy/sell signal about management sentiment.